"Interferon Type I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA).
| Descriptor ID |
D007370
|
| MeSH Number(s) |
D12.644.276.374.440.890 D12.776.467.374.440.890 D23.529.374.440.890
|
| Concept/Terms |
Interferon Type I- Interferon Type I
- Type I Interferons
- Interferons, Type I
- Interferons Type I
- Type I Interferon
- Interferon, Type I
|
Below are MeSH descriptors whose meaning is more general than "Interferon Type I".
Below are MeSH descriptors whose meaning is more specific than "Interferon Type I".
This graph shows the total number of publications written about "Interferon Type I" by people in this website by year, and whether "Interferon Type I" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1998 | 1 | 2 | 3 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 3 | 0 | 3 |
| 2010 | 2 | 1 | 3 |
| 2011 | 5 | 1 | 6 |
| 2012 | 2 | 2 | 4 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 2 | 3 |
| 2015 | 2 | 4 | 6 |
| 2016 | 4 | 2 | 6 |
| 2017 | 2 | 3 | 5 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 4 | 5 |
| 2022 | 3 | 1 | 4 |
| 2023 | 2 | 0 | 2 |
| 2024 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interferon Type I" by people in Profiles.
-
YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production. J Clin Invest. 2024 Dec 02; 134(23).
-
Cancer cells restrict immunogenicity of retrotransposon expression via distinct mechanisms. Immunity. 2024 12 10; 57(12):2879-2894.e11.
-
Poly I:C vaccination drives transient CXCL9 expression near B cell follicles in the lymph node through type-I and type-II interferon signaling. Cytokine. 2024 Nov; 183:156731.
-
A protective role for type I interferon signaling following infection with Mycobacterium tuberculosis carrying the rifampicin drug resistance-conferring RpoB mutation H445Y. PLoS Pathog. 2024 Apr; 20(4):e1012137.
-
Mycobacterium tuberculosis carrying the rifampicin drug-resistance-conferring rpoB mutation H445Y is associated with suppressed immunity through type I interferons. mBio. 2023 Oct 31; 14(5):e0094623.
-
SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck. Cell Rep. 2023 07 25; 42(7):112823.
-
NFKB2 haploinsufficiency identified via screening for IFN-a2 autoantibodies in children and adolescents hospitalized with SARS-CoV-2-related complications. J Allergy Clin Immunol. 2023 04; 151(4):926-930.e2.
-
Increased Type I interferon signaling and brain endothelial barrier dysfunction in an experimental model of Alzheimer's disease. Sci Rep. 2022 10 01; 12(1):16488.
-
Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor TÂ cell responses. Cancer Cell. 2022 10 10; 40(10):1145-1160.e9.
-
Myeloid cell interferon responses correlate with clearance of SARS-CoV-2. Nat Commun. 2022 02 03; 13(1):679.